The pharmacokinetics of gemtuzumab ozogamicin: An antibody-targeted chemotherapy agent for relapsed acute myeloid leukemia.

被引：0
|
作者：
Dowell, JA [1 ]
Berger, MS [1 ]
King, SP [1 ]
Korth-Bradley, J [1 ]
Liu, HJ [1 ]
机构：
[1] Wyeth Ayerst Res, Radnor, PA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
517
引用
收藏
页码：120A / 120A
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
    Dowell, JA
    Korth-Bradley, J
    Liu, HJ
    King, SP
    Berger, MS
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (11): : 1206 - 1214
  • [2] Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg)
    Sievers, EL
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (01) : 7 - 10
  • [3] Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    Larson, RA
    Boogaerts, M
    Estey, E
    Karanes, C
    Stadtmauer, EA
    Sievers, EL
    Mineur, P
    Bennett, JM
    Berger, MS
    Eten, CB
    Munteanu, M
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    [J]. LEUKEMIA, 2002, 16 (09) : 1627 - 1636
  • [4] Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia
    Williams, JP
    Handler, HL
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2000, 6 (18): : S975 - S985
  • [5] Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    RA Larson
    M Boogaerts
    E Estey
    C Karanes
    EA Stadtmauer
    EL Sievers
    P Mineur
    JM Bennett
    MS Berger
    CB Eten
    M Munteanu
    MR Loken
    JJM van Dongen
    ID Bernstein
    FR Appelbaum
    [J]. Leukemia, 2002, 16 : 1627 - 1636
  • [6] Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stadtmauer E.A.
    [J]. Current Oncology Reports, 2002, 4 (5) : 375 - 380
  • [7] Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
    Chantepie, Sylvain P.
    Reboursiere, Emilie
    Mear, Jean-Baptiste
    Gac, Anne-Claire
    Salaun, Veronique
    Benabed, Khaled
    Cheze, Stephane
    Johnsonansah, Hyacinthe
    Macro, Margaret
    Vilque, Jean-Pierre
    Reman, Oumedaly
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2326 - 2330
  • [8] Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.
    Sumbly, Vikram
    Landry, Ian
    Iqbal, Qamar
    Rehman, Mohammad Ebad Ur
    Chattaraj, Asmi
    Aijaz, Zobia
    Khattak, Zoia Ehsan
    Anwer, Faiz
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19006 - E19006
  • [9] Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia
    Buckwalter, M
    Dowell, JA
    Korth-Bradley, J
    Gorovits, B
    Mayer, PR
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 873 - 880
  • [10] Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Masters, Joanna C.
    Barry, Elly
    Knight, Beverly
    [J]. CLINICAL PHARMACOKINETICS, 2019, 58 (02) : 271 - 282
12345